Question · asked by 1 review

Chondroitin vs placebo: Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better)

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Chondroitin vs placebo
Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d Scale: millimeters (smaller decrease in reduction in minimum joint space width is better) · patients with osteoarthritis
Chondroitin for osteoarthritis (2015) · Cochrane Headline outcomes only
no estimate extracted2 studies · 922 participantsHigh

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Chondroitin for osteoarthritis
2015 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.